ALDX Stock — Aldeyra Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.36

Market cap

$82.0M

Cash

$45.1M

Enterprise value

$36.9M

Balance sheet

Cash	$45.1M
Debt	$0.0M
Net cash	$45.1M
Enterprise value	$36.9M
Basic shares	60.3M shares
Fully diluted shares	72.4M shares
Fully diluted market cap	$98.5M
Cash per share	$0.75

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALDX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	ICM ADX-2191 injection	Phase 3	Primary Vitreoretinal Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Reproxalap

Stage not disclosed · Active

Target reactive aldehyde species (RASP)

Partnerships AbbVie Inc: exclusive option agreement to enter a collaboration to develop/manufacture/commercialize reproxalap in the U.S. ($100M upfront on collaboration entry); option exercise period extended via $5M non-refundable fee; option tied to the FDA decision on the reproxalap NDA

Indications

Dry eye disease (Stage not disclosed)

Status note RASP modulator; NDA resubmission for dry eye disease pending FDA decision (the Reproxalap NDA). Filing states no clinical stage and no dated catalyst.

ADX-2191

Stage not disclosed · Active

Target Dihydrofolate reductase (DHFR)

Partnerships Licensed from MEEI (MEEI Patent Rights); proliferative-vitretinopathy rights obtained via Helio merger agreement

Indications

Primary vitreoretinal lymphoma (Stage not disclosed)
Retinitis pigmentosa (Stage not disclosed)
Proliferative vitreoretinopathy (Stage not disclosed)

Status note Novel formulation of intravitreal methotrexate per filing. Filing states no clinical stage and no dated catalyst.

ADX-248

Stage not disclosed · Active

Target reactive aldehyde species (RASP)

Indications

Systemic immune-mediated diseases (Stage not disclosed)
Retinal immune-mediated diseases (Stage not disclosed)

Status note RASP modulator portfolio asset. Filing lists it among compounds to advance through preclinical and clinical development but states no per-asset clinical stage.

ADX-246

Stage not disclosed · Active

Target reactive aldehyde species (RASP)

Indications

Systemic immune-mediated diseases (Stage not disclosed)
Retinal immune-mediated diseases (Stage not disclosed)

Status note RASP modulator portfolio asset. Filing lists it among compounds to advance through preclinical and clinical development but states no per-asset clinical stage.

ADX-629

Stage not disclosed · Terminated

Target reactive aldehyde species (RASP)

Status note Described in the filing as a signal-finding molecule no longer under development.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ICM ADX-2191 injection
Lead indication	Primary Vitreoretinal Lymphoma
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07402876	Phase 3	Recruiting	Sponsor	ALDX	—	Primary Vitreoretinal Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Aldeyra Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ALDX — Aldeyra Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials